Data on hemoglobin levels at the time of each transfusion were not captured in this study.
Also, we defined a composite hemoglobin safety endpoint based on laboratory data for hemoglobin declines of clinical concern and blood transfusion events.
It is evident that our model in Eq. (7), along with the values given in Tables 1 and 2, provide a good fit to the experimental data for hemoglobin concentrations of 15 g/dL and 33 g/dL.
Methods: In 54 patients with metastatic CRPC that underwent Xofigo therapy data on hemoglobin-levels (Hb), number of platelets (Plts) and leukocytes (Leuk) before, during and after therapy were collected.
In each individual set of hemoglobin data, we extracted data blocks from time course data.
Conclusion: These data suggest that normalization of hemoglobin levels in patients with CKD is safe.
Regarding laboratory data, the median values of hemoglobin level and white blood cells count were all included in the normal range; the median platelets count and lactate dehydrogenase were instead greater than normal values and less than half of the patients (44%) presented at physical examination with splenomegaly.
Data collection included measurement of hemoglobin levels, anthropometrics, blood lead levels (BLLs); a parental questionnaire including demographic and dwelling information; parents' occupation; and the child's duration of breastfeeding and food consumption.
Laboratory data revealed a high level of hemoglobin A1c (8.1%), but tumor markers, including carcinoembryonic antigen (2.1 ng/mL), cancer antigen-19-9 (15.4 U/mL), Dupan-2 (29 U/mL), and Span-1 (11.4 U/mL), were all within normal limits.
This first set of data suggests that the levels of hemoglobin binding, mutagenicity, and carcinogenicity of arylamines are not determined by the same electronic properties of the compounds, or not by these properties alone.
